Zetiq expects to obtain preliminary results during the second half of 2009.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company Zetiq Technologies Ltd. has obtained permits, including from an institutional review board (IRB), to conduct a smear study to test its technology for the early identification and diagnosis of cervical cancer. The study will be conducted in Hungary.
Zetiq expects to obtain preliminary results during the second half of 2009.
Zetiq has developed a set of proprietary tools to screen, monitor, and diagnose cancer by generating color discrimination between non-cancer cells and a wide range of cancer cells.
Biolight's share rose 0.8% by midday to NIS 1.15.
Published by Globes [online], Israel business news - www.globes-online.com - on June 4, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009